Angiotensin 1-7
Also known as Ang-(1-7) · Mas receptor ligand
Protective renin-angiotensin-system peptide studied for vascular, anti-inflammatory, and anti-fibrotic effects.
Evidence visual
Angiotensin 1-7 evidence and risk matrix
advanced researcher fit
Evidence
Tier B
Risk
low
Regulatory
investigational
WADA
none
FDA
none
Route
intravenous
Higher-confidence evidence profile, but regulatory and sourcing checks still matter.
Overview
Angiotensin 1-7 is a heptapeptide in the protective arm of the renin-angiotensin system. Small human studies and translational work suggest vascular, anti-inflammatory, and anti-fibrotic effects, but it remains investigational and route-specific. It is better understood than many fringe peptides, though still far from consumer-ready.
Decision path
Where Angiotensin 1-7 fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Angiotensin 1-7 belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Mas receptor agonist that promotes vasodilation, nitric-oxide signaling, and anti-inflammatory/anti-fibrotic effects.
intravenous, subcutaneous
Human research usually uses IV infusion protocols rather than routine self-administration.
Potential endothelial, anti-inflammatory, and anti-fibrotic benefits in vascular and pulmonary research settings.
Hemodynamic effects can appear quickly during infusion; structural outcomes are studied over longer periods.
Avoid in hypotension, volume depletion, and use caution with ACE inhibitors or ARBs.
Main practical risk is hypotension or reflex tachycardia, especially in combination with other RAAS-active therapies.
Likely additive blood-pressure lowering with ACE inhibitors, ARBs, and other vasodilating strategies.
Cost at a glance
No reliable cycle cost estimate yet. We need cleaner listing price and pack-size data before showing a trustworthy number.
Known Interactions
Both can shift vascular tone; combined use raises hypotension and perfusion-management uncertainty.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Angiotensin 1-7.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.